Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

iOmx Therapeutics AG. (2/3/22). "Press Release: iOmx Therapeutics Appoints Dr. Murray Yule as CMO to Lead Clinical Development". Martinsried.

Organisations Organisation iOmx Therapeutics AG
  Organisation 2 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Group MorphoSys (Group)
Products Product IMT-07 (iOmx Therapeutics)
  Product 2 IMT-18 (iOmx Therapeutics)
Index term Index term iOmx Therapeutics–MC Services: public relations, 202202 service existent by MC Services
Persons Person Yule, Murray (iOmx Therapeutics 202202– CMO before MorphoSys)
  Person 2 Papadimitriou, Apollon (iOmx Therapeutics 201910– CEO joined 2017 as CDO before Roche)

Lead program IMT-07 addressing a novel immune checkpoint target in solid tumors will enter clinical development in late 2022

iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, today announced the appointment of Dr. Murray Yule, M.D., Ph.D., as Chief Medical Officer (CMO), as of early January, 2022. Murray is a board-certified medical oncologist with extensive experience in leading clinical development programs. He has worked in the global pharmaceutical industry for over 20 years, planning and delivering clinical trials across the EU, US and Asia.

“This is an exciting time to work with iOmx and to implement the company’s clinical strategies for its first-in-class cancer immunotherapy programs IMT-07, a small molecule SIK3 inhibitor, and IMT-18, an IGSF11-targeting antibody,” said Dr. Murray Yule, Chief Medical Officer with iOmx. “I am delighted to join the outstanding team at iOmx at this important juncture and contribute to their successful transformation into a clinical stage organization. iOmx ´ approach to discover and target novel immune evasion biology is highly attractive to address the current gaps in cancer immunotherapy for patients in need. Our lead program, IMT-07, is currently proceeding with Clinical Trial Application (CTA)-enabling studies and aims to enter clinical development in late 2022.”

“Today, the majority of cancers remain resistant to current immunotherapies, with only a relatively small number of patients benefiting from these treatment options. Based on our research, we see that our next-generation immune checkpoint programs have the potential for single-agent efficacy in multiple solid tumors that are resistant to current therapies,” said Dr. Apollon Papadimitriou, CEO of iOmx. “It gives us great confidence to have the support of Dr. Yule, an experienced clinical oncologist and scientist. We are all looking forward to working with Murray to rapidly advance IMT-07 into the clinic and accelerate our other preclinical programs.”

Dr. Yule is a board-certified medical oncologist who trained in the United Kingdom and also at the MD Anderson Cancer Centre in Houston, Texas. Whilst working at Eisai he played a pivotal role in the successful development and approval of Eribulin for the treatment of advanced breast cancer and liposarcoma. Immediately prior to joining iOmx he worked on the FDA approval of Tafasitamab for the treatment of non-Hodgkin Lymphoma at MorphoSys. Dr. Yule has been a member of the Scientific Boards of Adcendo and Almac Discovery and has deep experience across a wide range of therapeutic approaches in the treatment of cancer ranging from small molecules to cellular therapy. He has extensive experience in partnering within the pharma industry and successfully listed Xynomic on the Nasdaq exchange.

About iOmx Therapeutics

iOmx Therapeutics ( is a biopharmaceutical company focused on developing first-in-class cancer immunotherapies addressing novel immune checkpoints hijacked by cancer cells. Utilizing its iOTarg™ high-throughput screening platform, iOmx has identified a number of proprietary tumor-associated next-generation immune checkpoints and is advancing a preclinical stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies. The company’s lead program IMT-07 targets SIK3, an immune protective kinase in multiple solid tumors; the IMT-18 program is a first-in-class antibody designed to inhibit IGSF11, an immune checkpoint in PD-1/PD-L1-resistant tumors. Founded in 2016 based on the work of its scientific founders Philipp Beckhove, MD, and Nisit Khandelwal, Ph.D., conducted at the German Cancer Research Center, iOmx is backed by international venture capital investors, such as Wellington Partners, Sofinnova Partners and M Ventures as well as MIG Capital and Athos Biopharma. iOmx is based in Martinsried/Munich, Germany.


MC Services AG
Katja Arnold, Julia von Hummel, Shaun Brown
T: +49(0)89 2102280

Record changed: 2023-06-05


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x200px

More documents for iOmx Therapeutics AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px

» top